Comparison of next-generation sequencing (NGS) and next-generation flow (NGF) for minimal residual disease (MRD) assessment in multiple myeloma

October 30th, 2020

AUTHORS
Alejandro Medina / Noemi Puig, Juan Flores-Montero / Cristina Jimenez / M.-Eugenia Sarasquete / María Garcia-Alvarez / Isabel Prieto-Conde / Carmen Chillon / Miguel Alcoceba / Norma C. Gutierrez / Albert Oriol / Laura Rosinol / Joan Bladè / Mercedes Gironella / Miguel T. Hernandez / Veronica Gonzalez-Calle / Maria-Teresa Cedena / Bruno Paiva / Jesus F. San-Miguel / Juan-Jose Lahuerta / Maria-Victoria Mateos / Joaquin Martinez-Lopez / Alberto Orfao / Marcos Gonzalez & Ramon Garcia-Sanz

The Laboratory for Personalized Molecular Medicine^® (LabPMM^®) at Invivoscribe offer internationally standardized testing of novel and proprietary biomarkers that are critically important for patient care.

Lymphoma

Myeloma

Browse our comprehensive menu of product & testing services.

A proven strategy to accelerate drug approvals

Design Controls, Bioinformatics Software, Identify & Track, Custom Development, and Complementary MRD Assays

cGMP Compliant, CE-marked IVDs & CDx Manufacturing, Assay Development, and Controls & Reagents

Clinical Lab Experience, Internationally Standardized, Comprehensive Panels, Complementary MRD Assays, and Worldwide Enrollment

Accredited & Proven, Registered Medical Device Establishment, Multiple CDx Approvals, CE-marked IVDs, and Marketing Authorization Holder (MAH)

We take pride in expanding the science that bridges personalized medicine with quality healthcare.

Personalized Molecular Medicine^® is use of genomics and patient specific information to identify optimal treatment for each patient.

November 17th, 2020
Routine Evaluation of Minimal Residual Disease in Myeloma Using Next-Generation Sequencing Clonality Testing

April 20th, 2021
Validation of a Next-Generation Sequencing-based T-Cell Receptor Gamma Gene Rearrangement Diagnostic Assay: Transitioning from Capillary Electrophoresis to Next-Generation Sequencing

November 17th, 2020
Routine Evaluation of Minimal Residual Disease in Myeloma Using Next-Generation Sequencing Clonality Testing

Lymphoma

Myeloma

Browse our comprehensive menu of product & testing services.